Letters to the editor antipsychotics has been discussed in the recent 2 decades. Some second-generation antipsychotics, such as olanzapine, risperidone, and clozapine, were reported to increase gray matter volume or prevent gray matter atrophy in patients with schizophrenia within 1 to 2 years. 6, 7 Also, recent time-lapse mapping analysis of brain structure in patients with schizophrenia suggested that those in an olanzapine treatment group would have less frontoparietal gray matter volume reduction than those in a haloperidol treatment group. 8 Reasons for gray matter growth effects might include the following: synaptic remodeling and neurogenesis 9 from the stimulation of neurotrophic factors by antipsychotics 10 ; prevention of oxidative stress or 6-OH-dopamine lesioning, with subsequent increased glial cell proliferation in frontal cortex 11 ; and modulation of glutamate receptor function. 12 These results were mostly based on schizophrenia or first-episode psychotic patients. Therapy duration was usually more than 12 weeks to 1 year.
In the present case, a patient with MDD and panic disorder received aripiprazole treatment and had response of symptoms and brain morphology change within 6 weeks. I hypothesize that aripiprazole's D 2 partial agonism might help the dopamine system stabilize and modulate neuronal activity through an inverted-U relationship. 13 Serotonin systems might stabilize as a result of the 5-HT 1A partial agonism and 5-HT 2C antagonism effects of aripiprazole. Serotonergic and dopaminergic actions of aripiprazole might help MDD and panic disorder symptoms improve. A role for aripiprazole as adjunctive therapy is already established for atypical or anxious MDD, 14 especially with antidepressants with serotonergic action. 15 An effect of aripiprazole as augmentation therapy in panic disorder is suggested, 16 but more randomized and well-controlled studies are needed to confirm the therapeutic effect.
Regarding the gray matter growth phenomenon, aripiprazole's D 2 partial agonism and 5-HT 2A and 5-HT 2C antagonism might produce gray matter growth that is similar to other atypical antipsychotics' effects in patients with schizophrenia. Aripiprazole was reported to modulate glutamate transporter gene expression 17 and promote brain-derived neurotrophic factor activity within 48 hours, 18 which might contribute to gray matter growth or brain volume increase. The relatively short duration (48 hours) of aripiprazole treatment in the animal model 17, 18 might explain this patient's 6-week findings of brain structure.
Apart from neurotransmitter theory, glial cell metabolic activity might also be relevant. A clozapine neuroimaging study showed that brain would express different metabolic activity patterns with clozapine than with haloperidol in patients with schizophrenia. mm, number of excitation = 1, slice thickness = 1 mm, 180 slices, no gap) were performed at the first visit and the 6-week visit. Ms A's body weight was 69.5 kg at baseline and 69.8 kg at the sixth week. Her hydration status remained similar, without significant differences in water or food intake between the 2 visits. Structural MRI was preprocessed with the structural image evaluation, using normalization, of atrophy, cross sectional version (SIENAX) function of FSL (FMRIB Software Library, Oxford, United Kingdom) to calculate single time point gray matter, white matter, and brain volume after registering and normalizing to template. The brain morphology change was estimated by SIENA function to calculate percentage brain volume change.
After analyzing MRI brain structure by SIENAX, we found that gray matter had increased from 674455.53 mm 3 to 720632.73 mm 3 within 6 weeks, and the percentage brain volume change was 0.054253 mm 3 , which suggested that Ms A's brain volume increased after aripiprazole treatment (Figure 1 ).
MDD and panic disorder have been reported to be associated with gray matter deficits in the amygdala, hippocampus, prefrontal cortex, and anterior cingulate cortex in past brain structure analysis reports. 4, 5 These regional gray matter deficits are related to symptom severity and even represent a kind of "trait marker" for these diseases. The relationship between gray matter and Letters to the editor polymorphism versus those who did not have this polymorphism. 20 When the modulating phenomenon of glial metabolism is combined with "neuron-glia" coupling activity seen in positron emission tomography 21 and glial cell proliferation evidence, 11 we can hypothesize that aripiprazole would modulate the brain glial cell activity of this patient and relate to the gray matter growth results.
To my knowledge, this is the first report of aripiprazole monotherapy in MDD with panic disorder. Neuroimaging evidence might help us explain the therapeutic effect of aripiprazole in MDD with panic disorder. Hopefully, this preliminary report will be confirmed by further research on aripiprazole monotherapy in MDD with panic disorder.
